Storia in 3 fonti

Screening India’s healthcare diagnostics market

Explore insights on India’s growing healthcare diagnostics market, highlighting opportunities and trends in Molbio Diagnostics' IPO prospectus.

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

m.economictimes.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo3 g fa

Screening India’s healthcare diagnostics market

Explore insights on India’s growing healthcare diagnostics market, highlighting opportunities and trends in Molbio Diagnostics' IPO prospectus.

originale

economictimes.indiatimes.com5 g fa

Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?

Molbio Diagnostics IPO raises ₹940 crore; revenue +31.5% over two years, net profit +40.2%, P/E ~57. TB kit dependency (70% revenue) and customer concentration (>50%) present risk; Truenat platform's 90-country reach and 22.6% EBITDA margins provide resilience.

Leggi questa versione →

Timeline cronologica

domenica 9 agosto 2026·economictimes.indiatimes.com
World Bank's IFC, HDFC AMC invest in Molbio Diagnostics' Rs 281 crore IPO anchor round
Molbio Diagnostics raised Rs 281 crore from anchor investors, including World Bank Group's IFC and HDFC Mutual Fund, ahead of its Rs 940 crore IPO opening on August 10. The…
lunedì 10 agosto 2026·economictimes.indiatimes.com
Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?
Molbio Diagnostics aims to secure ₹200 crore to enhance its capital expenditures through a new issuance of shares. In tandem, the firm intends to reduce promoter stake by…

Screening India’s healthcare diagnostics market

Confronto fonti

Screening India’s healthcare diagnostics market

Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?

Timeline cronologica

World Bank's IFC, HDFC AMC invest in Molbio Diagnostics' Rs 281 crore IPO anchor round

Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?

Molbio Diagnostics IPO opens: Should you subscribe for Rs 940 crore issue?

Molbio Diagnostics IPO: Analyst recommendations—should you subscribe or give it a miss?

Molbio Diagnostics IPO opens today: GMP at 15% — Check price band. Should you subscribe?

Molbio Diagnostics IPO opens: Should you subscribe for Rs 940 crore issue?

Molbio IPO Day 2: GMP hits at 17% listing gains. Should you bid?

Screening India’s healthcare diagnostics market

Molbio Diagnostics IPO Day 3: GMP hints at 17% listing gain, issue booked nearly 5x. Should you participate?

Molbio Diagnostics IPO allotment likely today; GMP at 20% — Here’s how to check status